News

News Archive

25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

Menarini Ricerche announces the completion of the dose escalation part of the First in Human, phase I/II DIAMOND trial (CLI24-001; NCT03008187) currently ongoing to evaluate SEL24/MEN1703
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq:...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More